First subcutaneous injection PD-1 declared clinical in China
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On May 28, Pfizer submitted a clinical application for PF-06801591 injections to be accepted by CDE, the first clinically declared subcutaneous injection pD-1 monoantigen in ChinaThe results of thePhase I clinical study (NCT02573259) showed that PF-06801591 was shown to be antitumor active in a variety of tumor types compared to intravenous injection every 4 weeks compared to intravenous injection every 3 weeks, and had good tolerance, and no serious skin toxicity was detectedPF-06801591's monthly subcutaneous administration can improve patient compliance and is expected to be an alternative to intravenous injectioncurrently, Corning Jerry's subcutaneous injection PD-L1 drug KN035 has entered phase III clinical stageIn addition, red-day pharmaceutical oral PD-L1 drug amedifen tablets have entered phase I clinical in ChinaPfizer/Merck PD-L1 drug Bavencio was approved by the FDA in 2017/3/23 and has been approved for three indications: Merkel cell tumor, urethra carcinoma and renal cell carcinomaBavencio is conducting clinical trials in China.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
